Beam Therapeutics Inc. (BEAM)
Chart Events
Performance Outlook
| Previous Close | 32.54 |
| Open | 34.08 |
| Bid | 33.40 x 1100 |
| Ask | 33.51 x 1300 |
| Day's Range | 32.61 - 34.97 |
| 52 Week Range | 27.77 - 138.52 |
| Volume | |
| Avg. Volume | 1,176,871 |
| Market Cap | 2.295B |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.54 |
| Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 99.20 |
- Simply Wall St.
Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
One thing we could say about the analysts on Beam Therapeutics Inc. ( NASDAQ:BEAM ) - they aren't optimistic, having...
- Zacks
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 8.18% and 89.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results
BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022 Natural History Study Initiated in People with Sickle Trait to Provide Insights into Key Characteristics of Sickle Cell Trait and Sickle Cell Disease Manmohan Singh, Ph.D., Appointed to Executive Leadership Team, and Anne Marie Woodland Appointed as Head of Regulatory Ended First Quarter 2022 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securitie
